Introduction: We have seen a significant evolution in the primary treatment goal for type two diabetes (T2D) over the last two decades. The first big shift came when a primary glucocentric approach, aimed at lowering glucose and HbA1c, evolved to incorporate a complications-centric approach, focused on reducing the downstream macro and microvascular complications such as cardiovascular disease, chronic kidney disease, and retinopathy. Arguably, the most significant shift, one which takes a more upstream, “root-cause” approach to managing T2D is currently underway. This shift to a “weightcentric” approach acknowledges the underlying pathophysiology of T2D as a disease that is both caused by, and complicated by, dysfunctional and excess fat accumulation, as such, making it an complication of the disease of obesity. For too long, obesity and T2D, have been treated as disparate disease states. Here, we will explore the critical intersection between these two disease states, with a specific focus on men, because men represent half of the population with the disease of obesity, but only 20% of people currently receiving treatment for the disease of obesity. Our aim is to help pharmacists recognize and understand the importance of treating obesity, both as a disease in its own right and as an upstream treatment for T2D, thus empowering pharmacists to play a pivotal role in supporting men living with obesity and T2D.
Obesity causes T2D through recognised pathophysiology, including insulin resistance, chronic inflammation, adipokine dysregulation, ectopic fat deposition, beta-cell dysfunction, hormonal imbalances, and gut microbiota alterations. Obesity is characterised by chronic low-grade inflammation of adipocytes (fat cells). Dysfunctional adipocytes secrete proinflammatory cytokines, such as TNF-alpha and interleukin-6 (IL-6), contributing to insulin resistance and directly impairing the function of pancreatic beta cells responsible for producing insulin. Adipocytes, being a metabolically active endocrine organ, also secrete hormones such as leptin (a regulator of adipocyte mass). Despite this, people living with obesity and T2D have pathognomonic symptoms of increased hunger and a lack of satiety.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.